Abstract:1 It has recently been shown that continuous infusions of 5-hydroxytryptamine (5-HT) are able to inhibit, in a dose-dependent manner, the pressor responses induced by preganglionic (T7-Tg) sympathetic stimulation in pithed rats pretreated with desipramine (50 mg kg- ', i.v.). This inhibitory effect, besides being significantly more pronounced at lower frequencies of stimulation (0.03-1 Hz) and devoid of tachyphylaxis, is reversible after interrupting the infusions of 5-HT (up to 5.6 pg kg-' min-'). In the pres… Show more
“…Moreover, the potentiation of sympathetically-induced vasopressor responses after desipramine made it possible to reveal more marked sympatho-inhibitory responses to quinpirole at lower stimulation frequencies ( fig. 3), as previously shown for other agonists [15,17,18]. This inhibition by quinpirole is not because of tachyphylaxis, as the sympathetic responses remained unchanged in animals receiving saline ( fig.…”
Section: Systemic Haemodynamic Changessupporting
confidence: 81%
“…4E), which are mainly mediated by a 1 -adrenoceptors [18]. Hence, haloperidol is not appropriate for analysing the pharmacological profile of receptors mediating sympatho-inhibition in our study, as similarly shown for other antagonists [18]. This attenuation by haloperidol could be due to blockade of vascular fig.…”
Section: Generalmentioning
confidence: 66%
“…Interestingly, haloperidol (a less selective D 2 -like receptor antagonist; table 1) attenuated per se the sympathetically-induced vasopressor responses ( fig. 4E), which are mainly mediated by a 1 -adrenoceptors [18]. Hence, haloperidol is not appropriate for analysing the pharmacological profile of receptors mediating sympatho-inhibition in our study, as similarly shown for other antagonists [18].…”
Section: Generalmentioning
confidence: 69%
“…before each S-R curve to block noradrenaline reuptake. Under these conditions, the vasopressor responses to lower stimulation frequencies are greater than those elicited without desipramine [16][17][18]. After 30 min., baseline values of diastolic blood pressure (a more accurate indicator of peripheral vascular resistance) and heart rate were determined.…”
This study investigated in pithed rats whether dopamine can inhibit the sympathetic vasopressor outflow and analysed the pharmacological profile of the receptors involved. Male Wistar pithed rats were pre-treated with intravenous (i.v.) bolus injections of gallamine (25 mg ⁄ kg) and desipramine (50 lg ⁄ kg). The vasopressor responses to electrical stimulation of the sympathetic vasopressor outflow (0.03-3 Hz; 50 V and 2 msec.) were analysed before and during i.v. continuous infusions of the agonists dopamine (endogenous ligand), SKF-38393 (D 1 -like) or quinpirole (D 2 -like). If inhibition was produced by any agonist, then its capability to inhibit the vasopressor responses to i.v. bolus injections of exogenous noradrenaline (0.03-3 lg ⁄ kg) was also investigated. Dopamine (3-100 lg ⁄ kg min.) inhibited the vasopressor responses to both electrical stimulation and noradrenaline. In contrast, SKF-38393 (10-100 lg ⁄ kg min.) failed to inhibit the vasopressor responses to electrical stimulation; whereas quinpirole (0.1-30 lg ⁄ kg min.) inhibited the vasopressor responses to electrical stimulation but not those to noradrenaline. The sympatho-inhibition by quinpirole (1 lg ⁄ kg min.) remained unaltered after i. Dopamine produces complex cardiovascular effects by interacting with a-and b-adrenoceptors and ⁄ or dopamine receptors [4,[6][7][8]. At the vascular level, D 1 -like receptors are mainly located on smooth muscle (mediating direct vasodilatation), whereas D 2 -like receptors are located on perivascular sympathetic nerves (mediating sympatho-inhibition) [4,9].Many studies have described the sympatho-inhibitory effects of dopamine on isolated blood vessels and other tissues [3], but no study has reported this effect on the systemic vasculature. For example, when analysing the sympathetic vasopressor outflow in pithed rats: (i) Hietala et al. [10] proposed that dopamine receptors may produce sympathoinhibition, but no selective antagonists were used; and (ii) Fernµndez et al.
Materials and MethodsGeneral methods. All animal protocols were approved by our Institutional Ethics Committee, in accordance with the guide for the Care and Use of Laboratory Animals in the USA. Experiments were carried out in 120 male Wistar normotensive rats (250-280 g). After anaesthesia with diethyl ether and cannulation of the trachea, the rats were pithed by inserting a stainless steel rod as reported earlier [12]. Then, the animals were artificially ventilated with room air using a model 7025 Ugo Basile pump (56 strokes ⁄ min.; stroke volume: 20 ml ⁄ kg), as previously established [13]. After bilateral vagotomy, catheters were placed in: (i) the left and right femoral veins, for the infusions of agonists and i.v. bolus injections of antagonists, respectively; and (ii) the left carotid artery, connected to a Grass pressure transducer (P23XL), for recording blood pressure. Both heart rate (measured with a 7P4F tachograph) and blood pressure were recorded simultaneously by a model 7D Grass polygraph (Grass Instrument Co., Quin...
“…Moreover, the potentiation of sympathetically-induced vasopressor responses after desipramine made it possible to reveal more marked sympatho-inhibitory responses to quinpirole at lower stimulation frequencies ( fig. 3), as previously shown for other agonists [15,17,18]. This inhibition by quinpirole is not because of tachyphylaxis, as the sympathetic responses remained unchanged in animals receiving saline ( fig.…”
Section: Systemic Haemodynamic Changessupporting
confidence: 81%
“…4E), which are mainly mediated by a 1 -adrenoceptors [18]. Hence, haloperidol is not appropriate for analysing the pharmacological profile of receptors mediating sympatho-inhibition in our study, as similarly shown for other antagonists [18]. This attenuation by haloperidol could be due to blockade of vascular fig.…”
Section: Generalmentioning
confidence: 66%
“…Interestingly, haloperidol (a less selective D 2 -like receptor antagonist; table 1) attenuated per se the sympathetically-induced vasopressor responses ( fig. 4E), which are mainly mediated by a 1 -adrenoceptors [18]. Hence, haloperidol is not appropriate for analysing the pharmacological profile of receptors mediating sympatho-inhibition in our study, as similarly shown for other antagonists [18].…”
Section: Generalmentioning
confidence: 69%
“…before each S-R curve to block noradrenaline reuptake. Under these conditions, the vasopressor responses to lower stimulation frequencies are greater than those elicited without desipramine [16][17][18]. After 30 min., baseline values of diastolic blood pressure (a more accurate indicator of peripheral vascular resistance) and heart rate were determined.…”
This study investigated in pithed rats whether dopamine can inhibit the sympathetic vasopressor outflow and analysed the pharmacological profile of the receptors involved. Male Wistar pithed rats were pre-treated with intravenous (i.v.) bolus injections of gallamine (25 mg ⁄ kg) and desipramine (50 lg ⁄ kg). The vasopressor responses to electrical stimulation of the sympathetic vasopressor outflow (0.03-3 Hz; 50 V and 2 msec.) were analysed before and during i.v. continuous infusions of the agonists dopamine (endogenous ligand), SKF-38393 (D 1 -like) or quinpirole (D 2 -like). If inhibition was produced by any agonist, then its capability to inhibit the vasopressor responses to i.v. bolus injections of exogenous noradrenaline (0.03-3 lg ⁄ kg) was also investigated. Dopamine (3-100 lg ⁄ kg min.) inhibited the vasopressor responses to both electrical stimulation and noradrenaline. In contrast, SKF-38393 (10-100 lg ⁄ kg min.) failed to inhibit the vasopressor responses to electrical stimulation; whereas quinpirole (0.1-30 lg ⁄ kg min.) inhibited the vasopressor responses to electrical stimulation but not those to noradrenaline. The sympatho-inhibition by quinpirole (1 lg ⁄ kg min.) remained unaltered after i. Dopamine produces complex cardiovascular effects by interacting with a-and b-adrenoceptors and ⁄ or dopamine receptors [4,[6][7][8]. At the vascular level, D 1 -like receptors are mainly located on smooth muscle (mediating direct vasodilatation), whereas D 2 -like receptors are located on perivascular sympathetic nerves (mediating sympatho-inhibition) [4,9].Many studies have described the sympatho-inhibitory effects of dopamine on isolated blood vessels and other tissues [3], but no study has reported this effect on the systemic vasculature. For example, when analysing the sympathetic vasopressor outflow in pithed rats: (i) Hietala et al. [10] proposed that dopamine receptors may produce sympathoinhibition, but no selective antagonists were used; and (ii) Fernµndez et al.
Materials and MethodsGeneral methods. All animal protocols were approved by our Institutional Ethics Committee, in accordance with the guide for the Care and Use of Laboratory Animals in the USA. Experiments were carried out in 120 male Wistar normotensive rats (250-280 g). After anaesthesia with diethyl ether and cannulation of the trachea, the rats were pithed by inserting a stainless steel rod as reported earlier [12]. Then, the animals were artificially ventilated with room air using a model 7025 Ugo Basile pump (56 strokes ⁄ min.; stroke volume: 20 ml ⁄ kg), as previously established [13]. After bilateral vagotomy, catheters were placed in: (i) the left and right femoral veins, for the infusions of agonists and i.v. bolus injections of antagonists, respectively; and (ii) the left carotid artery, connected to a Grass pressure transducer (P23XL), for recording blood pressure. Both heart rate (measured with a 7P4F tachograph) and blood pressure were recorded simultaneously by a model 7D Grass polygraph (Grass Instrument Co., Quin...
“…11 Centrally administered 8-OH-DPAT, a 5-HT1A receptor agonist, has been shown to decrease blood pressure and sympathetic nerve activity. 12 The sites of 5-HT release in the periphery are the gut and intestines. 13 Both of these areas have minimal blood flow during exercise.…”
Recent evidence from our laboratory and others have suggested that the mechanism for a decrease in resting blood pressure after an acute bout of exercise is a centrally mediated decrease in total peripheral resistance. This study examined the effect of the central serotonergic system on post exercise hypotension (PEH) in 11 borderline hypertensive individuals (nine male, two female) aged 24.5 ؎ 5.1 years. Each subject completed two, 30-min cycling bouts at 70% of V O 2 Peak while under placebo or a selective serotonin re-uptake inhibitor (SSRI) treatment. Blood pressure was recorded directly from the radial artery, and treatments were randomised, double blinded and separated by at least 14 days. Baseline blood pressure was 145/72 mm Hg for systolic (SBP) and diastolic (DBP) respectively. Peripheral measures of serotonin (5-HT) were lower under SSRI treatment, whereas the major 5-HT metabolite, 5-hydroxyindoleacetic acid, was not significantly changed,
It has recently been shown that the external carotid vasoconstrictor response to 5-HT in the dog is primarily mediated by sumatriptan-sensitive 5-HT1-like receptors; however, the fact that these receptors are not blocked by metergoline, a 5-HT1D ligand, raises questions about their possible correlation with the 5-HT1D receptor subtype. Since a number of drugs display high affinity for the 5-HT1D (GR127935) and 5-HT1F (e.g. methysergide and oxymetazoline) receptor subtypes, in this study we have used these drugs to determine whether the above vasoconstrictor 5-HT1-like receptors correlate with the 5-HT1D and/or 5-HT1F receptor subtypes. One-minute intracarotid infusions of 5-HT (0.3-30 micrograms/min), sumatriptan (1-30 micrograms/min), oxymetazoline (0.03-3 micrograms/min) and noradrenaline (0.3-3 micrograms/min) resulted in dose-dependent decreases in external carotid blood flow without changes in arterial blood pressure or heart rate. These vasoconstrictor responses remained unaltered after i.v. administration of physiological saline (0.015, 0.05 and 0.15 ml/kg; n = 4) or ritanserin (1 mg/kg; n = 5). In contrast, GR127935 (1, 3 and 10 micrograms/kg, n = 6) potently blocked the responses to 5-HT (unmasking a dose-dependent vasodilator component) and sumatriptan without affecting those to oxymetazoline or noradrenaline. Interestingly, methysergide (10, 30 and 100 micrograms/kg, n = 5) also blocked the vasoconstrictor responses to 5-HT and sumatriptan, but unlike GR127935, did not revert the vasoconstrictor response to 5-HT; the responses to oxymetazoline remained unaffected, but those to noradrenaline were apparently attenuated by the highest dose. Taken together, the above findings suggest that the sumatriptan-sensitive 5-HT1-like receptors mediating canine external carotid vasoconstriction resemble 5-HT1D receptors, probably of the 5-HT1D beta subtype on the basis of the resistance to blockade by ritanserin. The pharmacological profile of these receptors could be similar (bovine and human cerebral arteries, porcine carotid arteriovenous anastomoses and human coronary arteries) to other putative 5-HT1D receptors mediating vascular responses.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.